S&P Biotech index posts one of its worst single-day moves, Guy LeBas notes

S&P Biotech index posts one of its worst single-day moves, Guy LeBas notes
S&P Biotech index suffers rare decline

Guy LeBas highlights a significant move in the S&P Biotech index, noting a negative shift of two standard deviations. According to LeBas, there have been few days with worse single-day underperformance, with only one worse day in June 2026, two in 2023, two in 2022, and no comparably poor showings since 2017.

LeBas has previously commented on fixed income and equity flows at key market moments. In September, he reported increased buying of fixed income and selling of equities. He has also observed that U.S. Treasury auctions continued without event during recent issuances.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.